FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965425518> ?p ?o ?g. }

• W2965425518 abstract "e14714 Background: 30-40 % of PC pts present with LAPC. Optimal management remains controversial. Current NCCN guidelines, suggests clinical trial, FOLFIRINOX, G, G based combination therapy, chemo followed by CRT as options in pts with good PS. This single institution retrospective review, evaluated the UC experience of the impact of G+nab-p+/- CRT in LAPC. Methods: From 05/01/09-09/01/11,105 newly registered pts were identifiedusing ICD code 157, 13pts met inclusion criteria: ECOG PS 0-2, histologically proven LAPC, without prior therapy that received G + nab-P, pre or post radiation as part of their treatment. G+nab-p was given as cycles of G=1,000mg/m 2 and nab-P=100mg/m 2 weekly x3 every 4 weeks with appropriate modifications. CT scans and CA19-9 levels were followed. PFS was estimated from the date of diagnosis to date of progression or death if this occurred first and OS was estimated from date of diagnosis until date of death or loss to follow up. Kaplan Meier survival estimates were obtained with 95% confidence interval (CI). Log rank test was used to compare the PFS according to categorical variables. Results: Median duration of follow up was estimated to be 14.4 months (M) range(R) (5.8-19). CA19-9 data was available for 12 pts, 2 had baseline <1 (R<1-12,861), CA19-9 decrease > 50% from baseline was seen in 9/10. Mean # of G+nab-P cycles administered was 3, R (1-10). 77% received G based CRT with only 1pt receiving this post op. 38% (5/13) underwent resection, 4 post CRT with R0 margins and -ve LN’s and 1 pre CRT with R0 margins but 1/13 LN’s +ve. 11 pts were evaluable for response by RECIST (4PR, 6SD, 1PD). Disease control rate 91%. PFS 92% (CI: 57- 99%) at 6 M and 65% (CI: 31-85%) at 12 M. OS was 85% (CI: 51-96%) at 6M and 77 %(CI: 44-92%) at 12M. At 6M, 100% PFS was observed in resected group, whereas 88% PFS in non-resected group (p=0.12). There was no significant difference in PFS according to gender (p=0.44) and T lesion (p=0.49). Grade III/IV toxicity was mainly hematologic and gastrointestinal. (4/7) 57% received further therapy upon progression. Conclusions: Compared to contemporary G- based trials, the UC experience of G+ nab-P with CRT appears to be associated with improved survival in LAPC and warrants further study." @default.
• W2965425518 created "2019-08-13" @default.
• W2965425518 creator A5004149815 @default.
• W2965425518 creator A5009924885 @default.
• W2965425518 creator A5015568644 @default.
• W2965425518 creator A5015648940 @default.
• W2965425518 creator A5021452379 @default.
• W2965425518 creator A5029507131 @default.
• W2965425518 creator A5045839071 @default.
• W2965425518 creator A5056318563 @default.
• W2965425518 creator A5067793731 @default.
• W2965425518 creator A5081161607 @default.
• W2965425518 creator A5082070386 @default.
• W2965425518 creator A5083925701 @default.
• W2965425518 creator A5086753653 @default.
• W2965425518 creator A5091876744 @default.
• W2965425518 date "2012-05-20" @default.
• W2965425518 modified "2023-09-27" @default.
• W2965425518 title "Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)." @default.
• W2965425518 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e14714" @default.
• W2965425518 hasPublicationYear "2012" @default.
• W2965425518 type Work @default.
• W2965425518 sameAs 2965425518 @default.
• W2965425518 citedByCount "1" @default.
• W2965425518 countsByYear W29654255182013 @default.
• W2965425518 crossrefType "journal-article" @default.
• W2965425518 hasAuthorship W2965425518A5004149815 @default.
• W2965425518 hasAuthorship W2965425518A5009924885 @default.
• W2965425518 hasAuthorship W2965425518A5015568644 @default.
• W2965425518 hasAuthorship W2965425518A5015648940 @default.
• W2965425518 hasAuthorship W2965425518A5021452379 @default.
• W2965425518 hasAuthorship W2965425518A5029507131 @default.
• W2965425518 hasAuthorship W2965425518A5045839071 @default.
• W2965425518 hasAuthorship W2965425518A5056318563 @default.
• W2965425518 hasAuthorship W2965425518A5067793731 @default.
• W2965425518 hasAuthorship W2965425518A5081161607 @default.
• W2965425518 hasAuthorship W2965425518A5082070386 @default.
• W2965425518 hasAuthorship W2965425518A5083925701 @default.
• W2965425518 hasAuthorship W2965425518A5086753653 @default.
• W2965425518 hasAuthorship W2965425518A5091876744 @default.
• W2965425518 hasConcept C121608353 @default.
• W2965425518 hasConcept C126322002 @default.
• W2965425518 hasConcept C143998085 @default.
• W2965425518 hasConcept C2777292972 @default.
• W2965425518 hasConcept C2777844706 @default.
• W2965425518 hasConcept C2778424827 @default.
• W2965425518 hasConcept C2780210213 @default.
• W2965425518 hasConcept C2780258809 @default.
• W2965425518 hasConcept C2910430875 @default.
• W2965425518 hasConcept C71924100 @default.
• W2965425518 hasConceptScore W2965425518C121608353 @default.
• W2965425518 hasConceptScore W2965425518C126322002 @default.
• W2965425518 hasConceptScore W2965425518C143998085 @default.
• W2965425518 hasConceptScore W2965425518C2777292972 @default.
• W2965425518 hasConceptScore W2965425518C2777844706 @default.
• W2965425518 hasConceptScore W2965425518C2778424827 @default.
• W2965425518 hasConceptScore W2965425518C2780210213 @default.
• W2965425518 hasConceptScore W2965425518C2780258809 @default.
• W2965425518 hasConceptScore W2965425518C2910430875 @default.
• W2965425518 hasConceptScore W2965425518C71924100 @default.
• W2965425518 hasLocation W29654255181 @default.
• W2965425518 hasOpenAccess W2965425518 @default.
• W2965425518 hasPrimaryLocation W29654255181 @default.
• W2965425518 isParatext "false" @default.
• W2965425518 isRetracted "false" @default.
• W2965425518 magId "2965425518" @default.
• W2965425518 workType "article" @default.